Skip to content

Mesa Laboratories MLAB Change in Deferred Revenue

Change in Deferred Revenue at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$5.2M+528%
Personalis, Inc. logo
Personalis, Inc.PSNL
$2.61M+329%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$627K-208%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$2.61M+80.2%

Other financials

Income statement

See full
Revenue$63.7M+2.6%
Gross profit$31.2M-0.5%
Operating income-$664.0K+85.5%
Net income$3.6M+317%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$26.9M-1.4%
Total debt$78.7M-53.1%
Total equity$186.2M+16.5%
Total assets$427.7M-1.3%

Cash flow

See full
Operating cash flow$14.0M+10.2%
CapEx$417.0K-44.9%
Free cash flow$13.5M+13.7%

Valuation

See full
Market cap$542.27M+3.7%
Enterprise value$594.05M-10.4%
P/S2.2×0.0×

Profitability

See full
Gross margin56.8%
Operating margin2.3%
Net margin1.5%+0.8pp
FCF margin15.9%-1.8pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.6×
Current ratio1.7×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Mesa Laboratories’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Mesa Laboratories's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mesa Laboratories's change in deferred revenue?
Mesa Laboratories (MLAB) reported change in deferred revenue of -$813K in Q3 2025.
How has Mesa Laboratories's change in deferred revenue changed year-over-year?
Mesa Laboratories's change in deferred revenue decreased by 108.5% year-over-year, from -$390K to -$813K.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.